FDA Proposal Could Support Novo Nordisk GLP‑1 Exclusivity And Valuation
Simply Wall St
Last updated: May 2, 2026
The U.S. Food and Drug Administration (FDA) has proposed to remove semaglutide, tirzepatide, and liraglutide from federal compounding exemptions. This action would restrict pharmacies from compounding versions of these widely used GLP-1 receptor agonist medications.
- Key Facts: The FDA's proposal aims to prevent pharmacies from compounding drugs that are already available as FDA-approved products.
- Semaglutide, tirzepatide, and liraglutide are popular GLP-1 receptor agonists used for managing type 2 diabetes and, in some cases, for weight loss.
- Compounding involves mixing or altering existing drugs to create a new medication tailored to an individual patient's needs.
- The FDA's current compounding exemptions allow for the creation of drugs that are not commercially available, or for specific patient needs when approved medications are in shortage.
- Removing these specific drugs from the exemptions would mean that pharmacies generally could not compound them unless they meet strict criteria for a patient-specific prescription and are not commercially available.
- This move is likely influenced by the high demand and shortages of these medications, as well as concerns about the quality and safety of compounded versions.
- The proposal is currently open for public comment, allowing stakeholders to voice their opinions before a final decision is made.
- The intent is to ensure patients have access to safe, effective, and quality-controlled medications as approved by the FDA.
